New partnership with Thermo Fisher Scientific to build Civica’s internal pipeline of medications for use in emergency and critical care in the U.S.
Partnership with BCBS to bring lower cost Civica medicines to consumers through outpatient pharmacies
Civica and 18 Blue Cross Blue Shield plans announced an initiative to lower the cost of drugs for consumers. The effort, which focuses on a targeted list of generic drugs in the retail setting, provides opportunities for additional health plans, states, employers and pharmacies to join.
Civica begins providing discounted essential medications to 340B eligible hospitals to help serve high needs populations
Under Section 340B of the Public Health Service Act, pharmaceutical manufacturers participating in Medicaid also provide discounts on the prices of outpatient drugs to healthcare organizations that care for many uninsured and low-income patients.
These include public and nonprofit disproportionate share hospitals that serve low-income and indigent populations, community health centers, children’s hospitals, hemophilia treatment centers, critical access hospitals, sole community hospitals and rural referral centers.
Civica is named one of the 10 Most Innovative Not-for-profit Organizations of 2020
…for manufacturing generic drugs at lower prices to combat shortages and rising healthcare costs
“The news is filled with healthcare stories about people unable to afford their insulin, or companies driving up the cost of needed interventions like EpiPens. Civica Rx is a not-for-profit drug company designed to combat these horror stories, by creating stable supplies of generic drugs, to prevent them from having sudden price spikes. The company delivered its first drug, the antibiotic Vancomycin, this year.”
Meeting surge demands for COVID-19 patient care
“Hospitals created their own drug maker just in time for pandemic”
11 Civica medications used in clinical protocols to treat COVID-19 patients include broad spectrum antibiotics, pain management medications, neuromuscular blocking agents and medications needed to treat co-morbidities
Civica Rx partners with Phlow Corporation on near-term COVID-19 response and future “end-to-end” U.S.-based generic drug manufacturing
Announces plans to build a new Civica sterile injectable drug manufacturing facility
Civica provides 2.1 million vials of essential medicines for COVID-19 patients to the U.S. Strategic National Stockpile
Civica CEO Martin VanTrieste testifies before Congress on the security of the U.S. medicine supply chain
“The global coronavirus pandemic has highlighted weaknesses in the U.S. supply chain for essential medicines and other medical supplies…Many of the medicines used to manage COVID-19, including the sedatives and neuromuscular blocking agents essential for patients on ventilators, were already in short supply prior to the pandemic…Facing low margins and uncertain sales, companies are discouraged from investing in quality and incentivized to move production out of the U.S. to economies with lower labor costs, lower regulatory compliance costs and where they may receive direct or indirect support from foreign governments to build new facilities.”
Kaiser Permanente joins Civica to help secure supplies of essential generic medications during COVID-19 and beyond
Civica’s Governing board welcomes Kaiser
Sandoz partnership formed to reliably supply medicines for optimal patient care in acute care settings
Medications: Antibiotics, acid reducers, blood thinners, blood pressure regulators and medicines required in the operating room
Celebrating Civica’s 2nd Anniversary
From concept to today, Civica Rx (Civica, Inc) has proven to be a viable industry player, ensuring stable and predictable supplies of over 20 essential generic drugs so far, with an additional 20 under contract, and generating millions of dollars in savings for hospitals
Drug shortages can cause clinical and financial distress for patients and their families – medication errors, adverse events and increased out of pocket costs. For hospitals, drug shortages lead to increased costs due to price spikes and the need for more experts to manage shortages and search for the best possible alternative treatments.
As of September 2020, and one year after the first patient was treated with a Civica medication in Utah, Civica has delivered over eleven million vials and syringes to hospitals, treating up to 3 million patients across the United States.
In addition to stabilizing the supply of essential generic medicines, the collaborative Civica model has already saved health systems millions of dollars, with more savings to come.
Civica CEO Martin VanTrieste speaks at The National Academy of Science & Medicine on security of the U.S. medical supply chain
“There are steps we can take now to improve the resilience of our medicine supply chain.“
One Year Anniversary of Civica’s First Medication in Hospitals
A look back: Civica Board Chair Dan Liljenquist celebrates the 1st dose of a Civica medication being administered to a patient
STAT News Op-Ed: The U.S. needs to Support American-Made Medicines
“A diverse drug supply chain is a good insurance policy. But for essential drugs, in peacetime or pandemic, the U.S. should ensure that it can provide the medicines Americans need when we need them.”
A Revolution: Democratising Access to Medication
Civica board Chair Dan Liljenquist is interviewed by Ira Pastor, ideaXme life sciences ambassador. Dan share’s the Civica story from his concept to today.
To Date: 18M vials of Civica medications delivered, helping to treat over 7.5M patients